InMode (NASDAQ:INMD) Announces Earnings Results

InMode (NASDAQ:INMD) posted its quarterly earnings results on Tuesday. The healthcare company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.04, FiscalAI reports. The company had revenue of $103.85 million for the quarter, compared to the consensus estimate of $104.64 million. InMode had a net margin of 25.33% and a return on equity of 14.81%. InMode’s revenue was up 6.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.42 earnings per share.

Here are the key takeaways from InMode’s conference call:

• InMode expects 2026 to be a stabilization year, guiding 2026 revenue to $365M–$375M (broadly in line with 2025’s $370.5M) after a Q4 that showed slight improvement and a modest increase in consumables and services, which management views as early signs of patient activity stabilizing.
• International momentum drove a record Q4 in Europe: sales outside the U.S. were $48.5M (47% of Q4 revenue), up 38% YoY, and full-year international sales rose 15% to $171.8M, boosting geographic diversification.
• Product strategy emphasizes innovation and breadth — launched a CO2 platform in 2025 and plans to introduce a Korean-made Pico laser and a Morpheus+Erbium YAG combo in 2026 as part of a goal to release two new platforms per year to expand TAM and offer combined-treatment solutions.
• Management expects margin pressure in 2026 (NANGAP gross margin guided to 75%–77% vs. ~79% in 2025) and reported lower non‑GAAP operating margins and EPS YoY, attributing declines to lower‑margin imported laser products, U.S. tariffs on imports, and higher sales & marketing investments.
• Capital allocation and strategic review: InMode had $555.3M in cash/marketable securities, returned $127.4M to shareholders in 2025 (and ~ $508M via buybacks over prior years), and the board has engaged Bank of America to evaluate strategic alternatives while management’s involvement is limited.

InMode Price Performance

InMode stock traded up $0.13 during midday trading on Thursday, hitting $14.37. 77,841 shares of the stock were exchanged, compared to its average volume of 1,207,967. The company has a 50 day moving average price of $14.67 and a two-hundred day moving average price of $14.69. The firm has a market cap of $908.33 million, a P/E ratio of 10.00 and a beta of 2.19. InMode has a 1 year low of $13.14 and a 1 year high of $19.78.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on INMD shares. Weiss Ratings reissued a “sell (d+)” rating on shares of InMode in a research report on Thursday, January 22nd. Wall Street Zen cut InMode from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. UBS Group cut their price target on shares of InMode from $16.25 to $16.00 and set a “neutral” rating on the stock in a report on Thursday, November 6th. BTIG Research reaffirmed a “neutral” rating on shares of InMode in a research report on Monday, January 26th. Finally, Robert W. Baird set a $17.00 price objective on shares of InMode in a research note on Wednesday. One analyst has rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $16.80.

Institutional Trading of InMode

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. increased its position in shares of InMode by 48.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,422,635 shares of the healthcare company’s stock worth $20,899,000 after purchasing an additional 466,891 shares during the last quarter. Cooper Creek Partners Management LLC acquired a new position in InMode in the third quarter valued at approximately $14,980,000. Hotchkis & Wiley Capital Management LLC grew its holdings in shares of InMode by 9.9% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 899,090 shares of the healthcare company’s stock valued at $13,396,000 after purchasing an additional 81,170 shares during the last quarter. Bank of America Corp DE raised its position in shares of InMode by 142.1% during the 2nd quarter. Bank of America Corp DE now owns 862,209 shares of the healthcare company’s stock worth $12,450,000 after purchasing an additional 506,134 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of InMode by 0.6% during the 4th quarter. JPMorgan Chase & Co. now owns 649,188 shares of the healthcare company’s stock worth $9,537,000 after purchasing an additional 4,052 shares during the period. Institutional investors own 68.04% of the company’s stock.

InMode Company Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.